Avelas Biosciences is a clinical-stage oncology company focused on developing AVB-620, a novel drug-device combination product for use during cancer surgery. AVB-620 helps improve surgery by detecting cancer in real-time and has the potential to become part of standard-of-care treatment for a variety of cancer surgeries.

AVB-620 has been developed from pioneering technology originating in the lab of Nobel Laureate Roger Y. Tsien at the University of California – San Diego. AVB-620 is currently in a registration trial for detecting positive margins during breast cancer surgery.

Avelas has additional plans to investigate the product in a subset of other cancer surgeries, including ovarian, colorectal, head and neck, lung, melanoma, and sarcoma.